US HB7383 | 2023-2024 | 118th Congress
Status
Spectrum: Slight Partisan Bill (Republican 2-1)
Status: Introduced on February 15 2024 - 25% progression
Action: 2024-02-16 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on February 15 2024 - 25% progression
Action: 2024-02-16 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]
Summary
To amend the Federal Food, Drug, and Cosmetic Act to set forth limitations on exclusive approval or licensure of drugs designated for rare diseases or conditions.
Title
RARE Act Retaining Access and Restoring Exclusivity Act
Sponsors
Rep. Doris Matsui [D-CA] | Rep. Gus Bilirakis [R-FL] | Rep. Richard Hudson [R-NC] |
History
Date | Chamber | Action |
---|---|---|
2024-02-16 | House | Referred to the Subcommittee on Health. |
2024-02-15 | House | Referred to the House Committee on Energy and Commerce. |
2024-02-15 | House | Introduced in House |
Same As/Similar To
SB1214 (Related) 2023-06-22 - Placed on Senate Legislative Calendar under General Orders. Calendar No. 109.
HB3433 (Related) 2024-09-24 - Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
HB3433 (Related) 2024-09-24 - Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Subjects
US Congress State Sources
Type | Source |
---|---|
Summary | https://www.congress.gov/bill/118th-congress/house-bill/7383/all-info |
Text | https://www.congress.gov/118/bills/hr7383/BILLS-118hr7383ih.pdf |